APA (7th ed.) Citation

Nicum, S., Ledermann, J., Mileshkin, L., Jayson, G., Gourley, C., Michael, A., . . . Counsell, N. (2024). LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Annals of Oncology, 35, S1225. https://doi.org/10.1016/j.annonc.2024.08.2272

Chicago Style (17th ed.) Citation

Nicum, S., et al. "LBA33 ICON9: International Phase III Randomized Study to Evaluate the Efficacy of Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Patients with Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-based Chemotherapy." Annals of Oncology 35 (2024): S1225. https://doi.org/10.1016/j.annonc.2024.08.2272.

MLA (9th ed.) Citation

Nicum, S., et al. "LBA33 ICON9: International Phase III Randomized Study to Evaluate the Efficacy of Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Patients with Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-based Chemotherapy." Annals of Oncology, vol. 35, 2024, p. S1225, https://doi.org/10.1016/j.annonc.2024.08.2272.